CSF3 and Thrombocytopenia: Similar to the study results of Lai et al., our research revealed a lower rate of febrile neutropenia (1% of patients) and thrombocytopenia (2% of patients) as all of our patients on docetaxel received prophylactic granulocyte colony-stimulating factor (G-CSF) [12].